Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2FED 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Other hematologic neoplasm 1Gastrointestinal 1Breast 1

Conditions

Neuroblastoma 6Glioblastoma 6Melanoma 5Neoplasms 3Leukemia, Myeloid, Acute 3Glioma 3Colorectal Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pathologic Complete Response 2Ovarian Neoplasms 2Osteosarcoma 2Lung Neoplasms 2Liver Neoplasms 2Gliosarcoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Wilms Tumor 1Vaccinia 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma, Malignant 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02978222 2022-12-15

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Marker Therapeutics, Inc.

Phase 2 Terminated
120 enrolled 12 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡